Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Classifying childhood brain cancers by immune response may improve diagnostics and treatments

2.

Adjuvant therapy for hepatocellular carcinoma after curative treatment: Several unanswered questions

3.

Is global cancer care losing its human touch?

4.

After targeted agents, a novel bispecific in EGFR-mutant lung cancer improves PFS.

5.

FDA Approves New Bladder Cancer First-Line Standard of Care.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot